Introducing REXULTI® (brexpiprazole): a new PBS-listed antipsychotic for schizophrenia

October 1^st sees the PBS listing of REXULTI, a novel antipsychotic indicated for the treatment of adults with schizophrenia.

Patient Group Input Submissions: Brexpiprazole (Rexulti) - NCBI Bookshelf

Brexpiprazole - Mechanism of Action and Clinical Application

ex9902003.jpg

PDF) Construction and evaluation of a phospholipid-based phase transition in situ gel system for brexpiprazole

Full article: In vitro evaluations for pharmacokinetic drug-drug interactions of a novel serotonin-dopamine activity modulator, brexpiprazole

Otsuka and Lundbeck Announce U.S. Food and Drug Administration (FDA) Approval of Supplemental New Drug Application (sNDA) for REXULTI® ( brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer's Disease

ex9902009.jpg

Introduction - Clinical Review Report: Brexpiprazole (Rexulti) - NCBI Bookshelf

Discovery research and development history of the dopamine D2 receptor partial agonists, aripiprazole and brexpiprazole - Kikuchi - 2021 - Neuropsychopharmacology Reports - Wiley Online Library

REXULTI® (brexpiprazole) Adjunctive Use in Major Depressive Disorder

Not Everyone Agreed With FDA Approval of Antipsychotic Rexulti for Agitation - Mad In America

Full article: Pharmacokinetics and metabolism of brexpiprazole, a novel serotonin-dopamine activity modulator and its main metabolite in rat, monkey and human

Brexpiprazole - Mechanism of Action and Clinical Application

Table 2 from Brexpiprazole (Rexulti): A New Monotherapy for Schizophrenia and Adjunctive Therapy for Major Depressive Disorder.

Brexpiprazole - Mechanism of Action and Clinical Application